NCT06983028Phase 2Recruiting

Atacicept in Multiple Glomerular Diseases

Study sponsor: Vera Therapeutics, Inc. · VERA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-11Estimated

Enrollment · participants250Estimated

Source updated2026-06-26Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-26 · 1 field changed

Planned enrollment increased by 50 participants

− Before

~~200 participants (planned)~~

+ After

250 participants (planned)

Check registry source

Study details

Conditions studied

pMN; IgAN; Nephrotic Syndrome; MCD; FSGS

Treatments or interventions studied

AtaciceptDrug

Primary outcomes · main study measures

Read the study measures

measure: AE profile and results of routine clinical and laboratory tests; description: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), study drug discontinuation due to TEAEs; timeFrame: Baseline until end of study: 52 + 26 Weeks; measure: Percent reduction in urine protein to creatinine ratio (UPCR); description: Changes in proteinuria based on UPCR from 24 hour urine samples at baseline versus week 36; timeFrame: Baseline, Week 36

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history